1   A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in

2   acromegaly

3   Peter J Trainer,[1] John D C Newell-Price,[2] John Ayuk,[3] Simon J B Aylwin,[4] Aled Rees,[5] William

4   Drake,[6] Philippe Chanson,[7] Thierry Brue,[8] Susan M Webb,[9] Carmen Fajardo,[10] Javier Aller,[11] Ann I

5   McCormack,[12] David J Torpy,[13] George Tachas,[14] Lynne Atley,[14] David Ryder,[15] Martin

6   Bidlingmaier[16]

7

8

9   Correspondence to:

10   [1]Professor Peter J Trainer, Department of Endocrinology, The Christie NHS Foundation Trust,

11   University of Manchester, Manchester Academic Health Science Centre, Wilmslow Road,

12   Manchester, M20 4BX, UK

13

14   Peter.Trainer@manchester.ac.uk

15

16   Brief Title: Antisense oligomer treatment for acromegaly

17   Word count: 3998

19   [2]Department of Oncology and Metabolism, The Medical School, University of Sheffield, Beech Hill

20   Road, Sheffield S10 2RX, UK; Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS

21   Foundation Trust, Glossop Road, Sheffield, S10 2RF, UK.

22   [3]Consultant Endocrinologist and Honorary Senior Lecturer in Medicine Endocrinology, Queen

23   Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, B15 2TH, UK

24   [4]Consultant Endocrinologist, King's College Hospital, London, SE5 9RS, UK

25 [5]Reader and Consultant Endocrinologist, Neuroscience and Mental Health Research Institute, School

26 of Medicine, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff CF24 4HQ, UK

27 [6]Department of Endocrinology, St Bartholomew's Hospital, London, EC1A 7BE, UK

28 [7]Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Hôpital de Bicêtre,

29 Service d'Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre, F-94275, France;

30 Inserm 1185, Fac Med Paris Sud, Univ Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, F-

31 94276, France

32 [8]Aix-Marseille Université, CNRS, CRN2M UMR 7286, Marseille, France; APHM, Hôpital

33 Conception, Service d'Endocrinologie, Diabète et Maladies Métaboliques, Centre de Référence des

34 Maladies Rares d'Origine Hypophysaire, Marseille, France

35 [9]Department of Endocrinology, CIBERER group 747, IIB-S Pau, Hospital de la Santa Creu i Sant

36 Pau, Universitat Autonoma de Barcelona, Padre Claret 167 08025, Barcelona, Spain

37 [10]Servicio de Endocrinología. Hospital Universitario de La Ribera, Carretera de Corbera Km. 1,

38 46600 Alzira ,Valencia, Spain

39 [11]Endocrinology Department, Hospital Universitario Puerta de Hierro Majadahonda, C/Manuel de

40 Falla 1 28222 Majadahonda, Spain

41 [12]Garvan Institute of Medical Research and St Vincent's Hospital, 384 Victoria Street, Darlinghurst

42 Sydney NSW 2010, Australia

43 [13]Royal Adelaide Hospital, North Terrace, Adelaide 5000, Australia

44 [14]Antisense Therapeutics Limited, 6 Wallace Avenue, Toorak VIC 3142, Australia

45 [15]Manchester Academic Health Science Centre (MAHSC) Clinical Trials Unit, The Christie NHS

46 Foundation Trust, University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK

47

48 [16]Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-

49   Universität München, Ziemssenstraße 1, D-80336 Munich, Germany

51

Abstract

Objective:

ATL1103 is a second-generation antisense oligomer targeting the human GH receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly.

Design:

26 patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once- or twice-weekly for 13 weeks, and monitored for a further 8-week washout period.

Methods:

The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts. For secondary endpoints (IGFBP3, ALS, GH, GHBP), comparison was between baseline and week 14. Safety was assessed by reported adverse events.

Results and Conclusions:

Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups, respectivey. Compared to baseline, at week 14 twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% (p=0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (p=0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and at week 21 remained lower than at baseline by a median of 18.7% (p=0.0005).

Compared to baseline, by week 14 IGFBP3 and ALS had declined by a median of 8.9% (p=0.027) and 16.7% (p=0.017) with twice-weekly ATL1103; GH had increased by a median of 46% at week 14 (p=0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a median of 23.6% and 48.8% in the once- and twice-weekly cohorts (p=0.027 and p=0.005), respectively. ATL1103 was well tolerated, although 84.6% of patients experienced mild to moderate injection-site reactions (ISR).

This study provides proof-of-concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly.

4

80

Introduction

Acromegaly is a rare, chronic, life-shortening disease caused by hypersecretion of growth hormone (GH), virtually always due to a pituitary adenoma, that in turn results in elevated circulating levels of insulin-like growth factor 1 (IGF-I).[1] Conventional therapy is directed at the pituitary gland and attempts to reduce GH secretion by means of surgery, radiotherapy, or medical therapy in the form of somatostatin analogues and dopamine agonists.[2] The GH receptor antagonist pegvisomant has successfully exploited an alternative therapeutic approach, namely to block GH action rather than secretion.[3]

Antisense oligonucleotides (ASOs) are single-stranded synthetic oligonucleotides that have been developed as therapeutic agents. Translation of messenger RNA (mRNA), and hence protein synthesis, is inhibited by sequence-specific ASOs which bind target pre-mRNA and/or mRNA.[4] In the early 1990s, clinical trials with ASOs began, and in 1998 fomivirsen became the first oligonucleotide to be approved by the U.S Food and Drug Administration (FDA) for the treatment of cytomegalovirus retinitis.[5] In 2013, the second-generation ASO inhibitor mipomersen was approved by the FDA for the treatment of homozygous familial hypercholesterolaemia. Currently, there are more than 30 second-generation ASOs, including ATL1103, in clinical development for a variety of neurological, oncological, cardiovascular, and metabolic conditions. Excellent reviews of the technology are available elsewhere.[6]

ATL1103 is a second-generation, antisense oligomer designed to inhibit translation of human growth hormoe receptor (GHR) mRNA (Figure 1). It comprises 20 nucleotides with a phosphorothioate backbone and 2'-O-methoxyethyl modifications of the terminal five nucleotides at each end, which in combination increase its plasma half-life and affinity for the mRNA. Post-hybridization RNaseH degradation results in inhibition of GHR translation. In pre-clinical rodent and primate studies, ATL1103 reduced GHR mRNA levels in the liver and serum IGF-I, with a terminal half-life of 2 to 4 weeks (add Tachas JoE 2006 189 147) Phase 1 studies in healthy male volunteers demonstrated a fall in serum IGF-I and growth hormone binding protein (GHBP) (https://www.asx.com.au/asxpdf/20111207/pdf/4234016x2cj5xn.pdf).

110

The objectives of this study were to evaluate the safety, tolerability, and efficacy of ATL1103 in patients with acromegaly. Serum IGF-I was the primary measure of efficacy, with the other components of the IGF ternary complex, namely IGF-binding protein 3 (IGFBP3) and acid labile subunit (ALS) being additional measures of disease activity. Circulating GH and GHBP, the cleaved extracellular component of the GHR, were monitored to provide insight into the physiological implications of an ASO targeting the GHR. For the primary efficacy variable, the null hypothesis of no percentage change in fasting IGF-I levels from baseline to week 14 was tested for each treatment regimen.

Subjects and Methods

Study Design

This was a phase 2 randomised, open-label, parallel-group study of the safety, tolerability, pharmacokinetics, and efficacy of two subcutaneous dosing regimens of ATL1103 in patients with acromegaly (Figure 2).

Exclusion/Inclusion Criteria

Inclusion criteria
Patients who:
1. provided written informed consent in accordance with local regulations
2. were 18 to 80 years of age inclusive
3. had acromegaly due to pituitary adenoma (micro- or macroadenoma) identified by magnetic resonance imaging (MRI)
4. had serum IGF-I level at screening >1.3 times the upper limit of normal (ULN)

136   5. had documented serum GH nadir levels >1 ng/mL at all test time points within the 2 hours post

137   oral glucose load for an oral glucose tolerance test (OGTT) (this could be historical)

138   6. were acromegaly treatment naïve, or who had not taken other acromegaly medications for at

139   least the following periods of time prior to IGF-I and GH screening tests: bromocriptine: 6

140   weeks; carbergoline: 8 weeks; quinagolide: 8 weeks; octreotide (subcutaneous): 4 weeks;

141   pegvisomant: 8 weeks; octreotide LAR: 4 months; lanreotide (all presentations): 4 month

142   7. had a body mass index (BMI) $\geq$19 kg/m^2

143   8. had adequate venous access to allow collection of multiple blood samples during the study

144   9. were female of non-child-bearing potential (i.e., either surgically sterilised or at least 1 year

145   post-menopausal), or, if of child-bearing potential, agreed to use two approved methods of

146   contraception for the duration of the study and for 3 months after administration of the last dose

147   of study drug; or were male and surgically sterilised or agreed to use an approved method of

148   contraception for the duration of the study and until 3 months after administration of the last

149   dose of the study medication

150   10. were willing and able to self-administer subcutaneous injections

151

152 (Inclusion criteria 5, 6, and 9 were amended in protocol amendments during the study. For inclusion

153 criterion 5, the requirement for GH after OGTT at screening was altered, as this could be historical.

154 Inclusion criterion 6 was amended to clarify that the washout periods detailed were minimum periods.

155 For inclusion criterion 9, contraceptive requirements were clarified.)

156

157 Exclusion criteria

158 Patients who:

159   1. had acromegaly due to reasons other than pituitary adenoma

160   2. had a pituitary adenoma that was less than 3 mm distance from the optic chiasm

161   3. had undergone pituitary surgery within the 3 months preceding the Screening visit

162   4. had received pituitary radiotherapy within the 1 year preceding the Baseline visit

5. had insulin-treated diabetes, or had commenced a new hypoglycaemic drug for diabetes within the 2 months prior to Screening

6. had congestive heart failure, unstable angina, clinically significant cardiac arrhythmia, or a history of acute myocardial infarction within the 3 months preceding the Baseline visit

7. had abnormal hepatic function at Screening defined any of the following parameters >2 x ULN: aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), prothrombin time or total bilirubin

8. had hepatitis B, hepatitis C, or chronic liver disease

9. were pregnant or lactating

10. had known human immunodeficiency virus [(HIV) not tested specifically for this protocol], or history of immunodeficiency that may have compromised their safety or affect results from this study

11. had a history of alcohol or drug abuse in the 6 month period preceding the Baseline visit

Patients were recruited in 13 tertiary referral centres in Australia, France, Spain, and the United Kingdom.

Appropriate ethical approval was obtained in every jurisdiction, and the study was registered as EudraCT 201200314730 and ANZCTR 12611000854932. Patients gave written informed consent.

Procedures and Study Medication

Patients received either ATL1103 200 mg once or twice weekly 3 and 4 days apart for 13 weeks, with every patient receiving three doses in the first week, administered every other day. Based on the tissue half-life of >4 weeks, experience from primate studies and data from the phase 1 study, additional 'loading' doses were administered in the first week.

ATL1103 is formulated as a 'ready-to-inject' sterile solution at a concentration of 200 mg/mL, pH 7·4, in 'Water for Injection'. Patients were taught to self-administer ATL1103 subcutaneously. After

9

191 completion of drug administration at the end of 13 weeks, patients were monitored, off all therapy for

192 acromegaly, for a further 8 weeks.

193 All patients underwent pituitary MRI scans at baseline and at week 13 (completion of the study drug),

194 which were independently reviewed by two 'blinded' expert pituitary neurosurgeons. Tumour diameter

195 changes of 2 mm or more in any one dimension or tumour volume changes of more than 20% were

196 considered significant.

197

198 An OGTT with measurement of plasma glucose and serum GH was undertaken at baseline (after any

199 drug washout) and again at the end of week 13. An adverse event (AE) assessment was undertaken at

200 each of the 11 study visits from baseline until study conclusion.

201

202 In addition to routine safety parameters, serum IGF-I, insulin-like growth factor binding protein 3

203 (IGFBP3), ALS, and GHBP were monitored. Ring size (fourth digit left hand) was measured using

204 standard European-sized jewelers' ring sets, and patients completed a signs and symptoms score (SSS,

205 maximum score 40) and the disease-generated 'quality of life' AcroQol. AcroQol comprises 22

206 questions divided into two main categories: physical and psychological function. The psychological

207 category is further subdivided into appearance and personal relationships. Each question is scored out

208 of 5, with a maximum score of 110 reflecting best possible quality-of-life. The result is then converted

209 to a percentage.[7]

210

211 Randomisation and Blinding

212 Permuted block randomisation (generated by a statistician and imported into the electronic case report

213 form) was used to assign patients to either open-label, once- or twice-weekly ATL1003. Once initial

214 data for a patient had been entered and the patient had fulfilled all inclusion criteria, a randomisation

215 number and treatment regimen were generated. Treatment allocation was not known to the operational

216 personnel until this randomisation was performed.

217 Blocks of size 4 were used with no stratification for the first 24 patients. The list included an

218 additional 24 randomisation numbers using a block size of 2 (total 48) to allow for overage.

219

220 Assays

221 IGF-I, GH, and IGFBP3

222 Serum IGF-I, GH, and IGFBP3 were measured centrally by IDS-iSYS (Immunodiagnostic Systems,

223 [IDS] Ltd., Boldon, England, UK) assays at the Endocrine Laboratory, Universität München (Munich,

224 Germany). Recombinant standards (98/574 for GH and 02/254 for IGF-I) yielded inter-assay

225 variability of 4.0–8.7% (IGF-I) and 1.1–3.4% (GH) and sensitivity of 8.8 ng/mL (IGF-I) and 0.04

226 ng/mL (GH).[8, 9] The limit of quantification for IGFBP3 was 50 ng/mL and the intra- and interassay

227 coefficients of variation (CVs) were 4·2% and 6·9%, respectively.[10]

228

229 ALS

230 Serum ALS levels were measured in duplicate by sandwich immunometric assay using monoclonal

231 antibodies directed against specific N- and C-terminal oligopeptides.[11] A serum pool of healthy male

232 volunteers was used for calibration and assigned 1000 U/litre. The assay range is 500 to 5000 U/litre,

233 and the intra- and interassay CVs were less than 9%. All samples from an individual subject were

234 analysed in one run.

235

236 GHBP

237 Serum GHBP levels were measured by a modification of the ligand immunofunctional assay with an

238 in-house monoclonal anti-GHBP antibody. Within-assay CVs were 9.4% at 115 pmol/L and 6.1% at

239 1550 pmol/L. At the same concentrations, between-assay CVs were 8.5% and 10.9%, respectively.

240 The lower limit of quantification was 69 pmol/L, and the linear range was 69–3500 pmol/L. All

241 samples from an individual subject were analysed in one run.[12]

242

243 Statistics

244 The study was powered for within-group comparison of serum IGF-I (primary efficacy variable).

245 Based on a published pegvisomant study,[3] a clinically meaningful reduction in baseline IGF-I was

246 determined to be 27.5%, with a conservative estimate of standard deviation of 30%. To achieve a

247 level of significance of 0.05 with a two-sided test, it was determined that a minimum sample size of

248 12 patients per treatment was required to achieve a power of at least 80%.

249

250 The planned efficacy analyses were within the intention-to-treat group. For the primary efficacy

251 variable, the null hypothesis of no percentage change in fasting IGF-I levels from baseline to week 14

252 was tested for each treatment group with a (two-sided) one-sample *t* test and Wilcoxon signed rank

253 test. In addition, a pre-specified, though not powered for between-treatment-groups, comparison was

254 performed using a Wilcoxon Rank Sum test (mathematically equivalent to Mann-Whitney U test) for

255 serum IGF-I one week after the last dose of study drug (week 14).

256

257 Baseline to week 14 testing for both cohorts was undertaken (Wilcoxon signed rank test) for each of

258 the secondary endpoints (the other components of the IGF ternary complex, namely IGFBP3 and

259 ALS, plus circulating GH and GHBP, SSS, ring size, and AcroQoL) and presented as median plus

260 range.

261

262 A post-hoc regression analysis of the relationship between change in IGF-I and dose/kg/week is

263 reported with the associated 95% CI. Comparison of trapezoidal area-under-the-curve for GH during

264 the OGTTs is reported. Statistical significance is indicated by a p value <0.05.

265

266 Serum IGF-I data are expressed in mass units (ng/mL) and as a percentage of the upper limit of the

267 age-related reference range.

268

269 Data Safety Monitoring Board

270 An independent Data Safety Monitoring Board (DSMB) was established prior to recruitment start,

271 with an appropriate charter to direct decisions and monitor the trial safety results at intervals

272 throughout the study, and provided their recommendations as to whether the trial could continue as

273 planned or whether there were any concerns. The DSMB comprised four individuals with appropriate

274 experience in the areas of acromegaly, endocrine disorders, statistics, and the conduct of clinical

275 trials.

276

277 **Results**

278

279 Participants

280 Thirteen patients with active acromegaly (IGF-I >130% ULN at screening visit) (detailed in Table 1

281 and Figure 3) were recruited into each study arm.

282

283 Efficacy

284 IGF-I (Figures 4 and 5)

285

286 At baseline, the median serum IGF-I was 447 ng/ml (205–975)(2.5 x ULN) and 649 ng/ml (239–

287 831)(2.75 x ULN) ng/mL, in the once- and twice-weekly groups, respectively. Compared to baseline,

288 at week 14, ATL1103 at a dose of 200 mg twice weekly resulted in a median fall in serum IGF-I of

289 27.8% (range 4.4 to 49.8%, p=0.0002), while no change was seen with once-weekly dosing. At week

290 14, the median fall in IGF-I was 25.8% greater with twice-weekly compared to once-weekly dosing

291 (p=0.0012). In the twice-weekly cohort, IGF-I levels were still declining at week 14, and at the end of

292 the washout (week 21) remained lower than at baseline by a median of 18.7% (p=0.0005).

293

294 In both dosing regimens, one patient had an IGF-I within the age-related reference range at the pre-

295 defined endpoint of week 14. Normalisation of IGF-I at any time point was a pre-defined outcome

296 measure and was met by one additional patient in the twice-weekly regimen (week 13).

297

298 Combining the data from the two dosing regimens, regression analysis of the percentage change in

299 IGF-I levels versus dose/kg/week (median 2.88 (range 1.52 – 6.90) demonstrated an estimated slope

300 of regression of –8.27, indicative of a highly statistically significant (p=0.0001) association between

13

301   fall in IGF-I and the dose/kg/week (Figure 6).

302

303   IGFBP3

304   In the twice-weekly cohort, at week 14, there was a median fall in serum IGFBP3 of 8.9% (range -

305   29.2 to 12.9%, p=0.027) from baseline (median 7005 ng/ml, range 3396-9843). Once-weekly

306   ATL1103 did not result in a significant change in serum IGBP3.

307

308   ALS

309   Compared to baseline, twice-weekly ATL1103 resulted in a median fall in ALS at week 14 of 16.7%

310   (range -20.9 to 34.9%, p=0.017) from baseline (median 1970 mU/ml, range 945-2463). Once-weekly

311   ATL1103 did not result in a significant change in serum ALS.

312

313   GH (Figure 7)

314   In the twice-weekly cohort, median trapezoidal AUC for GH during the OGTT had increased by 46%

315   (range -5.4 to 419%, p=0.001) at week 14 compared to baseline (471 ng.min/ml (79-867)). There was

316   no change in GH levels in the once-weekly cohort.

317

318   GHBP (Figure 8)

319   There was a significant decline in serum GHBP levels in both cohorts at week 14. Twice-weekly

320   ATL1103 resulted in a median decline of 48.8% (range -9.8 to 94.1%, p=0.005) in GHBP from

321   baseline (525 pmol/l (<69-6434), while a median fall of 23.6% (range -61.4 to 59.4%, p=0.027) was

322   seen in the once-weekly cohort (1179 pmol/l (386-7637), p=0.027) and was maintained through to

323   week 21. In the twice-weekly cohort, the median fall in serum GHBP at week 21 was 40.4% (range -

324   94.1 to 6.1%, p=0.008) compared to baseline.

325

326   Ring Size

327 There was a statistically significant decrease in ring size circumference (mm) from baseline to week

328 13 for regimen 2, with a median decrease of –1·25 mm (range -12.6 to 3.8, p=0.039). Ring size was

329 unchanged with once-weekly dosing.

330

331 Signs and Symptoms Score

332 There was no marked difference in either regimen in median SSS at baseline (20 [1–36] vs 11 [7-30]).

333 The median percentage fall from baseline at week 14 was greater for twice-weekly dosing 37.5%

334 (range -185.7% to 91.7%) compared with 10.2% (range -33.3 to 83.3%) for once-weekly dosing,

335 although the changes were not statistically significant.

336

337 AcroQol

338 The median absolute improvement in the physical dimension and global scores between baseline and

339 week 14 in the once-weekly were 6.25 (range 0 to 31.3, p=0.002) and 3.4 (range -2.3 to 14.8,

340 p=0.0068) respectively, but these parameters did not change significantly with twice-weekly

341 ATL1103.

342 In contrast, in the twice weekly cohort, comparing baseline to week 14, the only significant finding

343 was an improvement in the median absolute change for the appearance subsection of psychological

344 dimension of 10.7 (range -17.9 to 25.0, p=0.035). There was no significant improvement in the once-

345 weekly cohort.

346

347 Safety (Table 2)

348 ATL1103 was well tolerated with mild to moderate injection site reactions (ISR) being the most

349 common, affecting 85% of patients in both cohorts, drug-related AE. Four serious AEs (SAEs) were

350 reported, of which three occurred in a single patient taking the once-daily regimen (acute bronchitis,

351 loss of consciousness while driving, and cholecystitis) and one in a patient taking the twice-daily

352 regimen (ear infection), but none were felt to be study drug–related, and both patients completed the

353 13 weeks of therapy. Two patients from one centre 'withdrew consent' at completion of dosing

354 (weeks 13 and 14) with study drug and so did not participate in the washout period through to week

355 21.

356

357 One patient in each regimen had low circulating platelet levels at a single time point (weeks 4 and 13,

358 86 and 132 x 10^9/L, respectively; normal range 150 x 10^9/L), but these resolved either spontaneously

359 or after treatment end (week 13). Two patients had elevated liver enzymes judged clinically

360 significant: one patient taking the once-daily regimen had γ-glutamyltransferase, AST, ALT, and ALP

361 values above the normal limit (>ULN); one patient taking the twice-daily regimen had AST and ALT

362 values >ULN. All effects on liver function were transient (Table 3).

363

364 The treatment-emergent AE (TEAE) profile was comparable for the two treatment groups

365 (Supplemental Table 2). Almost all patients experienced ISRs (mild and moderate), and 'mild'

366 lipohypertrophy, that subsequently, resolved was reported in two patients. There was a greater

367 incidence of headache in the once-weekly versus twice-weekly regimen (21 events and 5 events,

368 respectively), but the number of patients who experienced headache was comparable: 4 patients in the

369 once-daily regimen compared with 3 patients in the twice-daily regimen.

370

371 Radiologically significant tumour diameter changes (2 mm or more in any one dimension or tumour

372 volume changes of more than 20%) were reported in three patients. Tumour volume increased in two

373 patients (one in each dosing regimen, 5.7 x 7.3 x 19.1 v 6.8 x 9.9 x 19.5 mm and 8.1 x 5.8 x 14.8 v 8.1

374 x 7.2 x 16.2 mm) and reduced in one patient on twice-weekly dosing (6.2 x 10.4 x 4.9 v 2.6 x 5.7 x 4.1

375 mm). The changes were judged not to be clinically significant.

376

377 **Discussion**

378 The technology underpinning ASO therapy is rapidly advancing and has the potential to offer new

379 therapeutic options across a broad spectrum of diseases. Disordered protein production or function is

380 implicated in most pathological processes, and 'gene silencing or activating' by single-stranded

16

381   antisense oligonucleotides against target RNA sequences is an attractive concept that permits greater

382   specificity than can be achieved with small molecules or antibodies.[13] The synthetic structural

383   modifications, such as the phosphorothioate backbone and 2'-O- methoxyethyl modifications, can be

384   readily applied to whole classes of ASOs with only the nucleotide sequence being indication specific.

385   Encouraging studies of ASOs are being reported against many targets, but this is the first report of the

386   use of an ASO in endocrinology.

387   The data presented provide the 'proof-of-concept' that in patients with acromegaly an ASO targeting

388   the GHR can lower serum IGF-I and raise the prospect of a new and entirely novel therapy for

389   acromegaly. Thirteen weeks of ATL1103 at a dose of 200 mg twice weekly lowered median serum

390   IGF-I by 27.8%, with two (15%) of 13 patients achieving an IGF-I within the reference range. Serum

391   IGF-I levels were still declining at week 14 and had not returned to baseline by the end of the 8-week

392   (week 21) washout period (Figure 4), suggesting that the duration of ATL1103 therapy was too short

393   to see maximum benefit and that prolonged treatment at the same doses may result in a further decline

394   in serum IGF-I. First-order drug kinetics indicate that approximately four to five elimination half-lives

395   are required to achieve steady-state plasma concentrations; since the tissue half-life of ATL1103 is

396   believed to be >4 weeks,[14] this would suggest that between 16 to 20 weeks of treatment would be

397   required for nadir IGF-I levels to be achieved.

398

399   In conjunction with the data indicating a relationship between the dose per kilogram per week and the

400   fall in serum IGF-I, it seems probable that larger doses of ATL1103 administered for longer are likely

401   to result in a greater fall in IGF-I and offer the prospect of 'normalisation' of IGF-I in a greater

402   proportion of patients. Reassuringly, the decline in serum IGF-I with twice-weekly treatment was

403   paralleled by falls in the other elements of the IGF ternary complex, namely IGFBP3 and ALS.

404

405   Circulating GHBP is the product of cleavage of the extracellular component of the GH receptor.[15] In

406   acromegaly there is a negative correlation between serum GHBP concentrations and IGF-I and GH

407   levels (Kratzsch Eur J Endocrinol 1995;132(3): 306e12), such that in active acromegaly GHBP

As with pegvisomant, the reduction in serum IGF-I with twice-weekly ATL1103 was associated with a 46% increase in serum GH levels assessed during an OGTT. Studies with pegvisomant have demonstrated that the increased GH secretion is a consequence of negative feedback in response to the fall in circulating IGF-I induced by blocking GH action. [17]

It is encouraging that an improvement in the soft-tissue manifestations of acromegaly, indicated by the reduction in ring size, was seen with twice-weekly therapy. The short duration of therapy and small cohort size means it should not be a surprise that the fall in IGF-I was not associated with an improvement in SSS and only very modest improvements in quality of life as measured by AcroQol. Studies in larger numbers of patients treated for longer are required to demonstrate the impact of ATL1103 on well-being and quality of life.

Almost all patients, approximately 85%, experienced ISRs, but otherwise ATL1103 was generally well tolerated with no apparent drug-related SAEs. There were four SAEs, of which three occurred in one patient, and all were judged to be unlikely to be drug related; both patients completed the 13 weeks of therapy (Table 2). ISRs are a recognised side effect of second-generation ASOs; were mild to moderate in severity (predominantly a mixture of erythema, pain, and pruritus); and affected both cohorts equally. No patient withdrew from this study because of ISRs. This is a similar incidence of

ISRs as reported in other studies: 90% of patients participating in a phase 2 study of mipomersen experienced mild to moderate ISRs.[18] The mechanism of oligonucleotide-induced ISR is yet to be fully elucidated, but skin biopsies in 9 of 32 subjects participating in a phase 1 study of mipomersen were consistent with leukocytoclastic vasculitis (e.g., infiltrating neutrophils, prominent nuclear dust, lymphocytes, and eosinophils with local macrophage infiltration).[19] The lessons learned from the numerous other ASOs under clinical development will inform the management of ISRs in future studies of ATL1103. Transient changes in platelet count and liver function were encountered but were judged not to necessitate any change in therapy. Studies of greater length involving larger numbers of patients are required before any conclusions can be drawn about the safety profile of ATL1103.

There were no clinically significant changes in pituitary tumour size, but the short duration of treatment precludes meaningful conclusions about the long-term impact of ATL1103 on this parameter. Both the patients in whom tumour expansion of >2 mm was documented had discontinued somatostatin analogue therapy (one octreotide, one lanreotide) prior to commencing ATL1103, raising the possibility of rebound expansion from somatostatin analogue-induced tumour shrinkage. Reassuringly, the experience from more than 10 years' use of pegvisomant is that GHR-targeted therapy does not induce growth of pituitary adenomas.[20]

In summary, ATL1103 lowers IGF-I in acromegaly with biochemical changes consistent with down-regulation of the GHR. As IGF-I was still declining at the end of the treatment period and with the knowledge that the dose per kilogram could be increased, ATL1103 has the potential to achieve disease control in a significant proportion of patients. Placebo-controlled studies of longer duration and using higher doses are needed to better assess the full potential of this novel treatment.

Declaration of interests

472   **Author Contributions**

473   PJT contributed to the study design, identification of participating sites, and review of study data and

474   drafted the manuscript. JDCN-P participated in patient recruitment, contributed to drafting the

475   manuscript, and reviewed and approved the manuscript. JA, SJBA, AR, WD, PC, TB, SMW, CF, JA,

476   AIM, and DJT participated in patient recruitment and reviewed and approved the manuscript. GT and

477   LA were involved in protocol development and reviewed and approved the manuscript. DR was

478   responsible for the data analysis contained in the manuscript. MB contributed to the study design and

479   measurement of IGF-I, GH, IGFBP3, and ALS and reviewed and approved the manuscript.

480

484

20

References

485

486 1. Melmed S. Medical progress: Acromegaly. *N Engl J Med* 2006 **355** 2558-2573.

487 2. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der

488   Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S & Acromegaly

489   Consensus Group. Expert consensus document: A consensus on the medical treatment of

490   acromegaly. *Nat Rev Endocrinol* 2014 **10** 243-248.

491 3. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ,

492   Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO,

493   Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR,

494   Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips

495   LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of

496   acromegaly with the growth hormone-receptor antagonist pegvisomant. *N Engl J Med* 2000

497   **342** 1171-1177.

498 4. Vickers TA & Crooke ST. The rates of the major steps in the molecular mechanism of RNase

499   H1-dependent antisense oligonucleotide induced degradation of RNA. *Nucleic Acids Res*

500   2015 **43** 8955-8963.

501 5. Lundin KE, Gissberg O & Smith CI. Oligonucleotide therapies: the past and the present. *Hum*

502   *Gene Ther* 2015 **26** 475-485.

503 6. McClorey G & Wood MJ. An overview of the clinical application of antisense

504   oligonucleotides for RNA-targeting therapies. *Curr Opin Pharmacol* 2015 **24** 52-58.

505 7. Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C,

506   Pico A, Lucas A, Halperin I, Obiols G & Astorga R. Acromegaly Quality of Life

507   Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients

508   with acromegaly: development and psychometric properties. *Clin Endocrinol (Oxf)* 2002 **57**

509   251-258.

510 8. Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ & Bidlingmaier

511   M. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.

512   *Clin Chem* 2012 **58** 1446-1456.

513   9.   Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Körner A,

514   Obermayer-Pietsch B, Hübener C, Dahlgren J, Frystyk J, Pfeiffer AFH, Doering A,

515   Bielohuby M, Wallaschofski H & Arafat AM. Reference intervals for insulin-like growth

516   factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new

517   automated chemiluminescence IGF-I immunoassay conforming to recent international

518   recommendations. *J Clin Endocrinol Metab* 2014 **99** 1712-1721.

519   10.   Friedrich N, Wolthers OD, Arafat AM, Emeny RT, Spranger J, Roswall J, Kratzsch J, Grabe

520   HJ, Hübener C, Pfeiffer AFH, Döring A, Bielohuby M, Dahlgren J, Frystyk J, Wallaschofski

521   H & Bidlingmaier M. Age- and sex-specific reference intervals across life span for insulin-

522   like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by

523   new automated chemiluminescence assays. *J Clin Endocrinol Metab* 2014 **99** 1675-1686.

524   11.   Stadler S, Wu Z, Dressendorfer RA, Morrison KM, Khare A, Lee PD & Strasburger CJ.

525   Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site

526   immunoassay for ALS measurement in humans. *J Immunol Methods* 2001 **252** 73-82.

527   12.   Carlsson LM, Rowland AM, Clark RG, Gesundheit N & Wong WL. Ligand-mediated

528   immunofunctional assay for quantitation of growth hormone-binding protein in human blood.

529   *J Clin Endocrinol Metab* 1991 **73** 1216-1223.

530   13.   Goodchild J. Therapeutic oligonucleotides. *Methods Mol Biol* 2011 **764** 1-15.

531   14.   Geary RS, Norris D, Yu R & Bennett CF. Pharmacokinetics, biodistribution and cell uptake

532   of antisense oligonucleotides. *Adv Drug Deliv Rev* 2015 **87** 46-51.

533   15.   Schilbach K & Bidlingmaier M. Growth hormone binding protein - physiological and

534   analytical aspects. *Best Pract Res Clin Endocrinol Metab* 2015 **29** 671-683.

535   16.   Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ,

536   Lamberts SW, van der Lely AJ & de Herder WW. Postoperative evaluation of patients with

537   acromegaly: clinical significance and timing of oral glucose tolerance testing and

538   measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-

539   binding protein levels. *J Clin Endocrinol Metab* 2005 **90** 6480-6489.

540   17.   Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z & Strasburger CJ. Lowering total plasma

541   insulin-like growth factor I concentrations by way of a novel, potent, and selective growth

542   hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH

543   secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. *J Clin*

544   *Endocrinol Metab* 2001 **86** 3304-3310.

545   18.   Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R,

546   Baker BF, Wedel MK & Kastelein JJ. Efficacy and safety of mipomersen, an antisense

547   inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

548   *J Am Coll Cardiol* 2010 **55** 1611-1618.

549   19.   Food and Drug Administration. FDA Briefing Document NDA 203568; Mipomersen Sodium

550   Injection 200 mg/mL; Applicant: Genzyme Corporation; Endocrinologic and Metabolic

551   Drugs Advisory Committee Meeting. 2012.

552   20.   van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J,

553   Lundgren F, Rajicic N, Strasburger CJ, Webb SM & Koltowska-Haggstrom M. Long-term

554   safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in

555   ACROSTUDY. *J Clin Endocrinol Metab* 2012 **97** 1589-1597.

556

557

558 **Tables**

559 **Table 1: Baseline Characteristics of Patients With Acromegaly**

	200 mg ATL1103 once weekly	200 mg ATL1103 twice weekly
	Median (range)	Median (range)
Number of patients	13	13
Age – *years*	49 (26–72)	49 (32–80)
Sex – *M/F*	5/8	6/7
Duration of disease[*] – *years*	9.0 (1–24)	3 (<1–20)
Weight – *kg*	90.6 (73.4–113.9)	83.2 (58–131.6)
Height – *cm*	169 (154–194)	163 (148–197)
Body mass index – *kg/m²*	31.8 (26.0–39.6)	29·4 (21.4–45.3)
Size of adenoma at diagnosis – *no. (%)*		
Micro (<10 mm)	2 (18%)	2 (16.7%)
Macro (> or = 10 mm)	9 (81.8%)	10 (83.3%)
Missing	2	1
Hypopituitarism at study entry – *no. (%)*	4 (30.8%)	4 (30.8%)
Previous therapy – *no. (%)*		
Surgery	13 (100%)	12 (92.3%)
Radiotherapy (all modalities)	6 (46.2%)	5 (38.5%)
Dopamine agonist therapy	3 (23%)	5 (38.5%)
Somatostatin analogue therapy	11 (84.6%)	12 (92.3%)

24

Pegvisomant therapy	7 (53.8%)	5 (38.5%)
Serum growth hormone - *ng/mL*	3.6 (0.4–60.6)	3.5 (1.5–9.4)
GH nadir (Screening OGTT) – *ng/mL*	2.5 (0.29–54.69)	2.4 (0.37–5.52)
Serum IGF-I – *ng/mL*	447 (205–975)	642 (239–831)[†]
Serum GHBP – *pM*	1179.0 (386–7637)	525.0 (<69–6434)[‡]
Serum IGFBP-3 – *ng/mL*	6589.0 (5162–9630)	7005.0 (3396–9843)
ALS – *mU/mL*	1669.0 (1395–2829)	1970.0 (945–2463)
Ring size circumference – *mm*	63.8 (57.5–81.4)	67.5 (53.7–78.9)
AcroQoL – *global score*	58 (18–100)	71 (56–90)
SSS – *calculated maximum score*	20.0 (1–36)[§]	11 (7–30)

GH, growth hormone; OGTT, IGF-I, insulin-like growth factor 1; GHBP,growth hormone binding protein; ALS, acid labile subunit; IGFBP-3 , insulin-like growth factor binding protein 3; SSS, signs and symptoms score.

*Years from initial diagnosis to first day of study.

[†]Baseline IGF-I missing for one patient, screening IGF-I value used for calculations.

[‡]n=12, baseline GHBP missing for one patient.

[§]n=12, baseline SSS missing for one patient.

Table 2. Summary of Treatment-emergent Adverse Events (Safety Set)*

	200 mg once weekly (n=13)			200 mg twice weekly (n=13)			Total (N=26)		
	n	N	%	n	N	%	n	N	%
TEAEs	98	11	84.6	88	11	84.6	186	22	84.6
Drug-related TEAEs[†]	33	6	46.2	24	8	61.5	57	14	53.8
Serious TEAEs	3	1	7.7	1	1	7.7	4	2	7.7
Severe drug-related TEAEs	0	0		0	0		0	0	
Severe TEAEs	6	3	23.1	1	1	7.7	7	4	15.4
TEAEs leading to permanent discontinuation of study drug	0	0		0	0		0	0	
Withdrawals	1[§]			1[§]					
Patients with ISR	11		84.6	11		84.6	22		
Mild		9			6			15	
Moderate		2			5			7	
Severe		0			0			0	
Most frequent TEAEs with a >15% incidence									
Headache	21	4	30.8	5	3	23.1	26	7	26.9
Fatigue	3	2	15.4	3	2	15.4	6	4	15.4
Diarrhoea	3	2	15.4	2	2	15.4	5	4	15.4
Constipation	2	2	15.4	2	2	15.4	4	4	15.4
Dizziness	1	1	7.7	4	2	15.4	5	3	11.5
Hyperhidrosis	1	1	7.7	4	2	15.4	5	3	11.5
Rash	3	1	7.7	2	2	15.4	5	3	11.5
Abdominal pain upper	1	1	7.7	2	2	15.4	3	3	11.5
Nasopharyngitis	2	2	15.4	1	1	7.7	3	3	11.5
Urinary tract infection	3	2	15.4	0	0		3	2	7.7
Oropharyngeal pain	0	0		3	2	15.4	3	2	7.7
Abdominal distension	0	0		2	2	15.4	2	2	7.7
Abdominal pain	0	0		2	2	15.4	2	2	7.7

Tracheitis	2	2	15.4	0	0		2	2	7.7
Carpal tunnel syndrome	2	2	15.4	0	0		2	2	7.7
Haematuria	2	2	15.4	0	0		2	2	7.7
Lipohypertrophy	2	2	15.4	0	0		2	2	7.7

ISR, injection site reaction; N, number of patients; n, number of events; %, percentage of patients; TEAE, treatment-related adverse event.

[*]Excludes ISRs.

[†]Drug related is defined as relationship to study drug = possible, probable, or definite.

[§]Withdrew consent after last drug dose.

570

571

572
573
574
575

576

577 **Table 3. Summary of Abnormal Liver Function Tests.**

Analyte	Week	Result	Reference range
200 mg once weekly			
↑GGT, U/L	8	159 (repeats: 65, 32)	8–61
	21	102	
↑AST, U/L	8	111 (repeats: 70, 26)	6–40
↑ALT, U/L	8	181 (repeat: 135)	6–40
↑ALP, U/L	8	200	40–128
200 mg twice weekly			
↑AST, U/L	4	42	2–31
	8	43	
↑ALT, U/L	4	69	8–34
	8	99	
	13	52	
↑Total bilirubin (μmol/L)	1	28	0–21
	2	22	
	4	26	

578 GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase;

579 ALP, alkaline phosphatase.

580

581   **Figures**

582

583   **Figure 1. Cartoon representation of ATL1103 and the mechanism of antisense inhibition.**

584   ATL1103 is a second-generation, 20-mer antisense oligonucleotide with a phosphorothioate backbone

585   and 2'-O-methoxyethyl modifications of the terminal five nucleotides at each end, which in

586   combination increase its plasma half-life and affinity for the mRNA. Post-hybridization RNaseH

587   degradation results in inhibition of GHR translation.

588

589

590   GHR, growth hormone receptor.

591

Figure 2. Schematic representation of study protocol.

The protocol entailed appropriate washout from any ongoing acromegaly medical therapy after which

serum IGF-I had to be at least >1.3 times age-related ULN. All patients underwent pituitary MRI

scans at baseline and completion of the study drug. An OGTT was undertaken at baseline (after

washout) and again at the end of week 13.

IGF-I, insulin-like growth factor 1; ULN, upper limit of normal; MRI, magnetic resonance imaging;

OGTT, oral glucose tolerance test.

602 **Figure 3. Patient disposition.**

603

604

605 [a]Five patients failed screening as IGF-I was <130% ULN.

606 [b]Although powered for 12 patients per arm, 13 were included per arm since a commitment had been

607 made to allow patients consented and 'passing' screening to receive study drug.

608 IGF-I, insulin-like growth factor 1; ULN, upper limit of normal.

609

610

Figure 4. Median percentage change from baseline in serum concentrations of IGF-I in patients

with acromegaly.

613 In the patients randomised to ATL1103 200 mg twice weekly, the median fall in serum IGF-I was

614 27.8% (p=0.0002[a]) at the end of the treatment phase (week 14, 1 week after the last dose of study drug)

615 compared to baseline (week 0). Between cohort analysis at week 14 demonstrated the median fall in

616 serum IGF-I to be 25.8% (p=0.0012) with twice- compared to once-weekly dosing. In the twice-weekly

617 cohort, IGF-I was still declining at week 14, and at week 21 remained lower than at baseline by a median

618 of 18.7% (p=0.0005[b]).

619

620

621

622   <mark>medians and interquartile ranges plotted</mark>
623

624

625

626

627 **Figure 5. Percentage change in serum IGF-I levels from baseline to week 14 in 26 patients**

628 **treated with 200 mg ATL 1103 once or twice weekly.**

629

630

631 IGF-I, insulin-like growth factor .

632

633 **Figure 6. Scatterplot of the percentage change from baseline in IGF-I at week 14 by the**

634 **allocated dose per kg per week.**

635 Combining the data from the two dosing regimens demonstrated a highly statistically significant

636 (p=0.0001) correlation with an estimated slope of regression of –8.27 (95% CI –11.97 to –4.56).

637

638 IGF-I, insulin-like growth factor 1; CI, confidence interval.

Figure 7. Trapezoidal AUC for GH during OGTTs at baseline and week 14.

In the twice-weekly cohort, the median increase in AUC was 46% at week 14 compared to baseline (p=0.001). There was no change in GH levels in the once-weekly cohort.

AUC, area under the curve; GH, growth hormone; OGTT, oral glucose tolerance test; CI, confidence interval.

Figure 8. <mark>Median percentage change from baseline in serum concentrations of GHBP in patients with acromegaly.</mark>

<mark>Twice-weekly ATL1103 resulted in a median decline of 48.8% in GHBP (p=0.005[a]) at week 14 (open symbols), while a median fall of 23.6% was seen in the once-weekly cohort (p=0.027[a]). In the twice weekly cohort, at week 21 the median fall in GHBP, compared to baseline, was 40.4% (p=0.008[b]).</mark>

<mark>medians and interquartile ranges plotted</mark>